About 200 reports

Autoimmune phenomena in non-Hodgkin lymphoma.

  • Lung Cancer
  • World
  • AbbVie Inc.
  • Aduro BioTech, Inc.
  • Amgen Inc.
  • OPDIVO'S DEVELOPMENT IN NSCLC
  • PRESENTS AN OVERVIEW OF OPDIVO'S DEVELOPMENT PROGRAM IN NSCLC.

THIS STUDY INCLUDED BOTH PD-L## NEGATIVE TWO WEEKS) OR DOCETAXEL (##MG/ M (##%) AND PD-L## POSITIVE (##%) PATIENTS, BUT EXCLUDED PATIENTS WITH AUTOIMMUNE DISEASE, SYMPTOMATIC ILD, AND UNTREATED BRAIN METASTASIS.

  • Lung Cancer
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

MONOCLONAL ANTIBODIES ARE ALSO HIGHLY UTILIZED IN AUTOIMMUNE DISEASE TREATMENT.

  • Lung Cancer
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

UNDERSTANDING THE DISEASE PART ##: Disease overview NON-SMALL CELL LUNG CANCER IS ONE OF THE MOST COMMON TYPES OF CANCER.

  • Lung Cancer
  • AstraZeneca PLC
  • Celgene Corporation
  • Hoffmann-La Roche Inc.
  • Pfizer Inc.

Orphanet Journal of Rare Diseases; ##: ##-## Leiter U and Garbe C (2008).

  • Lung Cancer
  • World
  • Market Size
  • Celgene Corporation
  • Merck & Co., Inc.

Infectious disease: Lymph node enlargement may be due to a variety of infectious or autoimmune diseases.

  • Lung Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

Infectious disease: Lymph node enlargement may be due to a variety of infectious or autoimmune diseases.

  • Lung Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

WITHOUT SUCH CHECKPOINTS, THE IMMUNE CELLS WILL ATTACK NORMAL CELLS OF THE BODY RESULTING IN AUTOIMMUNE DISEASES.

  • Lung Cancer
  • North America
  • United States
  • Incyte Corporation
  • Merck & Co., Inc.
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..4), H1 2018

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018 Summary Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes...

  • Lung Cancer
  • Oncology
  • Pharmaceutical
  • Therapy
  • Exelixis, Inc.

Medimmune undertake research in the areas of cancer treatment; respiratory; inflammation and autoimmune; and cardiovascular disorders and metabolic diseases.

  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • MedImmune, LLC
  • PIPELINE BY INCYTE CORP, H2 2018
  • PIPELINE BY IMMUTEP LTD, H2 2018

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2018 Summary Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 26 molecules. The latest report Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2...

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • PLX-7486 - DRUG PROFILE
  • PLX-7486 - DRUG PROFILE

It focuses on therapy areas such as respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases.

  • Lung Cancer
  • United States
  • World
  • Product Initiative
  • Ignyta, Inc.
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies...

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Exelixis, Inc.
  • ENTRECTINIB - DRUG PROFILE

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Lung Cancer
  • United States
  • World
  • Product Initiative
  • Ignyta, Inc.

Monoclonal Antibody to Antagonize PD-## for Autoimmune Disorders and Oncology Bispecific mab is under development for the treatment of autoimmune diseases and cancer.

  • Cancer Immunotherapy
  • Lung Cancer
  • Oncology
  • Therapy
  • Merck & Co., Inc.
  • Pipeline by Etubics Corp, H2 2018
  • Pipeline by OSE Immunotherapeutics, H2 2018

OSE' s Effi-## is in preclinical development and targets autoimmune diseases and transplantation.

  • Lung Cancer
  • Therapy
  • World
  • Product Initiative
  • Etubics Corporation
  • PIPELINE BY MERCK & CO INC, H1 2018
  • PIPELINE BY ADURO BIOTECH INC, H1 2018

The company develops drugs for cardiovascular, oncology, metabolic, pain, CNS, autoimmune and infectious disease applications.

  • Lung Cancer
  • Renal Cancer
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

Its other clinical programmes include TZLS-##, a human engineered anti-human CD## antibody intended for the treatment of autoimmune and inflammatory diseases.

  • Cancer
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Cyclacel Pharmaceuticals, Inc.
  • Pipeline by OSE Immunotherapeutics, H1 2018
  • Pipeline by Etubics Corp, H1 2018

OSE' s Effi-## is in preclinical development and targets autoimmune diseases and transplantation.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Etubics Corporation
  • GSK-3174998 - DRUG PROFILE

It focuses on therapy areas such as respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

Results Overall in BRCA positive patients (Parts ## and ##, n=##), disease control rate is ##. ##% and overall response rate (ORR) is ##% (Part ## ORR ##% and Part ## ##%).

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Cyclacel Pharmaceuticals, Inc.

Deal Type Deal in Brief TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases.

  • Lung Cancer
  • Therapy
  • United States
  • Company
  • Checkpoint
  • September 23, 2018.
  • PEMBROLIZUMAB - DRUG PROFILE

Patients with active, non-infectious pneumonitis, an allogeneic transplant within the past five years (or more than five years but with graft-versus-host-disease [GVHD]), active autoimmune disease or a medical condition that required immunosuppression were ineligible for e

  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Merck & Co., Inc.
  • PEMBROLIZUMAB - DRUG PROFILE

Patients with active, non-infectious pneumonitis, an allogeneic transplant within the past five years (or more than five years but with graft-versus-host-disease [GVHD]), active autoimmune disease or a medical condition that required immunosuppression were ineligible for e

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

Rheumatoid arthritis is an autoimmune disease that most commonly develops in women aged from ## to ##.

  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Japan
  • Chugai Pharmaceutical Co., Ltd.
  • entrectinib - Drug Profile

Among two evaluable MET- patients, one had stable disease and one had progression.

  • Lung Cancer
  • Therapy
  • United States
  • World
  • Product Initiative
  • target action, date of April 3, 2018.
  • PEXIDARTINIB HYDROCHLORIDE - DRUG PROFILE

Plexxikon announced in January that enrollment started for the first of two Phase ## clinical trials with PLX##, a novel, oral, targeted and highly selective Fms kinase inhibitor for the treatment of autoimmune diseases such as RA.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.
  • PLX-7486 - DRUG PROFILE
  • ENTRECTINIB - DRUG PROFILE

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Lung Cancer
  • Oncology
  • United States
  • Product Initiative
  • Exelixis, Inc.
  • target action, date of April 3, 2018.

Only ## patient had progressive disease.

  • Hospital
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative

In the Medium-Term Management Plan ##-## Open Up the Future, Mitsubishi Tanabe Pharma has positioned autoimmune diseases as one of its priority disease areas.

  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Ono Pharmaceutical Co., Ltd.